2026 ICD-10-CM Diagnosis Code C08.0Malignant neoplasm of submandibular gland
ICD-10-CM Codes›C00–D49›C00-C14›C08
- Billable — Valid for Submission
- Risk Adjusts — HCC 21
- Chronic Condition
C08.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of submandibular gland. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 11 through 13, 146 through 148. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Head and neck cancers - salivary gland.
For Medicare Advantage risk adjustment, C08.0 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C08.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adenoid cystic carcinoma of salivary gland
- Adenoid cystic carcinoma of submandibular gland
- Carcinoma of submandibular gland
- Malignant neoplasm of submandibular salivary gland
- Mucoepidermoid carcinoma of salivary gland
- Mucoepidermoid carcinoma of submandibular gland
- Primary adenocarcinoma of submandibular gland
- Primary adenoid cystic carcinoma of salivary gland
- Primary adenoid cystic carcinoma of submandibular gland
- Primary carcinoma ex pleomorphic adenoma of salivary gland
- Primary carcinoma ex pleomorphic adenoma of submandibular gland
- Primary carcinoma of submandibular gland
- Primary malignant neoplasm of submaxillary gland
- Primary mucoepidermoid carcinoma of salivary gland
- Primary mucoepidermoid carcinoma of submandibular gland
- Primary squamous cell carcinoma of submandibular gland
- Squamous cell carcinoma of head and neck
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Malignant neoplasm of submaxillary gland
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Submandibular Gland
one of two salivary glands in the neck, located in the space bound by the two bellies of the digastric muscle and the angle of the mandible. it discharges through the submandibular duct. the secretory units are predominantly serous although a few mucous alveoli, some with serous demilunes, occur. (stedman, 25th ed)Submandibular Gland Diseases
diseases involving the submandibular gland.Submandibular Gland Neoplasms
new abnormal growth of tissue in the submandibular gland.Squamous Cell Carcinoma of Head and Neck
the most common type of head and neck carcinoma that originates from cells on the surface of the nasal cavity; mouth; paranasal sinuses, salivary glands, and larynx. mutations in tnfrsf10b, pten, and ing1 genes are associated with this cancer.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| salivary gland or duct (major) › submandibular | C08.0 | C79.89 | D00.00 | D11.7 | D37.032 | D49.0 |
| salivary gland or duct (major) › submaxillary | C08.0 | C79.89 | D00.00 | D11.7 | D37.032 | D49.0 |
| submandibular gland | C08.0 | C79.89 | D00.00 | D11.7 | D37.032 | D49.0 |
| submaxillary gland or duct | C08.0 | C79.89 | D00.00 | D11.7 | D37.032 | D49.0 |
| Wharton's duct | C08.0 | C79.89 | D00.00 | D11.7 | D37.032 | D49.0 |
Patient EducationClinical
Salivary Gland Cancer
Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C08.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C08.0Overview
What is the ICD-10 code for malignant neoplasm of submandibular gland?
The ICD-10-CM code for malignant neoplasm of submandibular gland is C08.0 (sometimes written as C080). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is C08.0 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of submandibular gland on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C08.0 group to?
When malignant neoplasm of submandibular gland is the principal diagnosis on an inpatient stay, it groups to MS-DRG 11, 12, 13, 146, 147, 148, with relative weights from 0.7971 to 5.4541 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C08.0?
Under the General Equivalence Mappings, malignant neoplasm of submandibular gland converts to ICD-9-CM 142.1 (malig neo submandibular). The mapping is a direct match.
What HCC is C08.0?
C08.0 (malignant neoplasm of submandibular gland) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C08.0 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C08.0 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.
